<SEC-DOCUMENT>0001213900-17-004710-index.html : 20170508
<SEC-HEADER>0001213900-17-004710.hdr.sgml : 20170508
<ACCEPTANCE-DATETIME>20170508091340
ACCESSION NUMBER:		0001213900-17-004710
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170508
FILED AS OF DATE:		20170508
DATE AS OF CHANGE:		20170508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Therapix Biosciences Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1213

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		17820775

	BUSINESS ADDRESS:	
		STREET 1:		5 AZRIELI CENTER (SQUARE TOWER)
		CITY:			TEL-AVIV
		STATE:			L3
		ZIP:			6702501
		BUSINESS PHONE:		972-3-6167055

	MAIL ADDRESS:	
		STREET 1:		5 AZRIELI CENTER (SQUARE TOWER)
		CITY:			TEL-AVIV
		STATE:			L3
		ZIP:			6702501
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k050817_therapixbio.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
Document 1 - file: f6k050817_therapixbio.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f6k050817ex99i_therapixbio.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY THERAPIX BIOSCIENCES LTD. ON MAY 8, 2017, ANNOUNCING THAT IT ENTERED INTO AN INVESTIGATOR-INITIATED CLINICAL TRIAL AGREEMENT WITH THE HANNOVER MEDICAL SCHOOL TO ASSESS THE EFFECT OF TXH-TS01 IN PATIENTS WITH TOURETTE SYNDROME
<TEXT>
Document 2 - file: f6k050817ex99i_therapixbio.htm

</DOCUMENT>
</SEC-DOCUMENT>